# A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan

> **NCT00199290** · PHASE2 · COMPLETED · sponsor: **Kaken Pharmaceutical** · enrollment: 267 (actual)

## Conditions studied

- Periodontitis

## Interventions

- **DRUG:** Trafermin (genetical recombination)

## Key facts

- **NCT ID:** NCT00199290
- **Lead sponsor:** Kaken Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-07
- **Final completion:** 2007-12
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2008-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00199290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00199290, "A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00199290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*